Key facts
- Bluejay Therapeutics’s last known valuation is $820.0M.
- It has raised $243.0M across 3 recorded rounds; the latest was Later Stage VC (Series C) ($182.0M) in May 2024.
- Notable investors include RA Capital Management, Novo Holdings, Wellington Management, T. Rowe Price Group, Frazier Healthcare Partners — 13 tracked in total.
- Bluejay Therapeutics has filed 3 Form Ds with the SEC since 2021, most recently May 2024 ($182.0M sold to 19 investors).
- Status: In IPO Registration.
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for Bluejay Therapeutics
Funding rounds
3 roundsAbout Bluejay Therapeutics
Developer of therapeutic medicines designed to provide curative treatments for serious viral and liver diseases. The company's treatment focuses on reducing viral surface antigen monoclonal antibodies for the restoration of adaptive immunity starting with chronic hepatitis B (CHB) and chronic hepatitis D (CHD), enabling patients to improve their immunity and recover from infection.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- Redwood City, CA, United States
- Founded
- 2019
- Employees
- 38
- Website
- bluejaytx.com/
- Ownership
- In IPO Registration
Bluejay Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Bluejay Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Bluejay Therapeutics in its N-PORT filings yet. We sweep new filings monthly.